FGFR1 and hepatocellular carcinoma: Several studies have reported that lenvatinib is more effective than sorafenib in treating HCC with macrovascular invasion, this may be owing to the potent activity against FGFR1–4 is a distinctive feature of lenvatinib, compared with sorafenib (33–36).